A retrospective study by Kratochwil and colleagues (2018) reported on the outcomes of [225Ac]Ac-PSMA-617 PRRT as a salvage last-line therapy on 38 eligible heavily pretreated advanced PCa patients [54]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.